Abstracts tagged "SLE"

Abstract Number: 722 • 2015 ACR/ARHP Annual Meeting
Biomarkers/Pathways Discovery of Lupus Nephritis By Urine Proteomics
Michelle Petri¹, Wei Fu², Adnan Kiani¹, Lauren DeVine¹, Conover Talbot Jr.¹ and Robert Cole¹, ¹Johns Hopkins University School of Medicine, Baltimore, MD, ²Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: We have previously validated several urine proteomic biomarkers for Lupus Nephritis (osteoprotegerin, MCP-1, VCAM-1 and urine TWEAK). In this discovery effort we looked for…
Abstract Number: 808 • 2015 ACR/ARHP Annual Meeting
Heritable Endotheliopathy and ApolipoproteinL1 Risk Traits in SLE
Ashira Blazer¹, Andrew Markham², Sara Rasmussen³, Jill P. Buyon⁴, H. Michael Belmont⁵, Shilpi Mehta-Lee⁶, Janet Nwaukoni⁴, Peter M. Izmirly⁷ and Robert Clancy⁴, ¹Division of Rheumatology, NYU School of Medicine, New York, NY, ²Medicine, New York University School of Medicine, New York, NY, ³Department of Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY, ⁴Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY, ⁵Hosp for Joint Disease, New York, NY, ⁶Obstetrics and Gynecology, New York University School of Medicine, New York, NY, ⁷Rheumatology, NYU School of Medicine, New York, NY
Background/Purpose: With higher prevalence of renal and cardiovascular diseases (CVD), as well as HTN, African American (AA) SLE patients experience accelerated damage accrual and excess…
Abstract Number: 1754 • 2015 ACR/ARHP Annual Meeting
BANK1 Controls the Development of SLE By Modulating TLR7 Signaling and Type I IFN-Induced Translation Initiation Pathway in B Cells
Ying-Yu Wu¹, Ramesh Kumar², Harini Bagavant¹ and Marta E. Alarcon Riquelme³, ¹Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Oklahoma Medical Research Foundation, Oklahoma Cty, OK, ³Arthritis & Clinical Immunology, Oklahoma Medical Research Foundation, Center for Genomics and Oncological Research Pfizer-University of Granada-Junta de Andalucia, Oklahoma City, OK
Background/Purpose: BANK1 is a susceptibility gene for SLE, and we have shown that stimulation of TLR9 agonist leads to a reduction in the activation of…
Abstract Number: 1858 • 2015 ACR/ARHP Annual Meeting
Serum Tartrate Resistant Acid Phosphatase (TRAP) Levels Are Decreased and Associated with Anti-Maa Antibodies in Systemic Lupus Erythematosus (SLE) Patients
Kathleen Borghoff¹, Andy Hollins², Michael J. Duryee¹, Ted R. Mikuls², Zhixin Zhang³, Kaihong Su⁴, Michelene Hearth-Holmes⁵ and Geoffrey M. Thiele⁶, ¹Internal Medicine Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE, ²University of Nebraska Medical Center, Omaha, NE, ³Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, NE, ⁴Pathology and Microbiology, University of Nebraska Medical Center, Omaha, NE, ⁵Division of Rheumatology, University of Nebraska College of Medicine and VA Nebraska Western Iowa Health Care System, Omaha, NE, ⁶Omaha VA Medical Center and University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Previous studies have shown that patients with systemic lupus erythematosus (SLE) are prone to systemic osteoporosis, bone loss and fracture. Paradoxically, previous studies…
Abstract Number: 2929 • 2015 ACR/ARHP Annual Meeting
Diet and Glucocorticoid Treatment in Patients with SLE
Cecilia Lourdudoss¹, Johan Frostegård² and Ronald F. van Vollenhoven³, ¹Dept. of Medicine, ClinTRID, Karolinska institutet, Stockholm, Sweden, ²Karolinska Institutet, Section of Immunology and chronic disease, Institute of Environmental Medicine, Stockholm, Sweden, ³Department of Medicine, Unit for Clinical Therapy Research, Inflammatory Diseases (ClinTRID), The Karolinska Institute, Stockholm, Sweden
Background/Purpose: Relatively little is known about the link between diet and treatment results in SLE. Glucocorticoids (GC) are used to control active SLE but minimized…
Abstract Number: 3223 • 2015 ACR/ARHP Annual Meeting
Anifrolumab, an Anti-Interferon Alpha Receptor Monoclonal Antibody, in Moderate to Severe Systemic Lupus Erythematosus (SLE)
Richard Furie¹, JT Merrill², VP Werth^3,4, M Khamashta⁵, K Kalunian⁶, P Brohawn⁷, G Illei⁷, J Drappa⁷, L Wang⁷ and S Yoo⁸, ¹North Shore-LIJ Health System, New York, NY, ²Oklahoma Medical Research Foundation, Oklahoma City, OK, ³Philadelphia V.A. Medical Center, Philidelphia, PA, ⁴University of Pennsylvania, Philadelphia, PA, ⁵Graham Hughes Lupus Research Laboratory, The Rayne Institute, St Thomas' Hospital, London, United Kingdom, ⁶UCSD School of Medicine, La Jolla, CA, ⁷MedImmune, Gaithersburg, MD, ⁸Regenx Bio, Rockville, MD
Background/Purpose: The efficacy and safety of anifrolumab (ANIFR), a type I IFN receptor antagonist, were assessed in a Phase II, randomized, double-blind, placebo-controlled study in…
Abstract Number: 726 • 2015 ACR/ARHP Annual Meeting
Associates of Pleurisy of Pericarditis in Systemic Lupus Erythematosus (SLE)
Seungwon Ryu¹ and Michelle Petri², ¹Konkuk University School of Medicine, Seoul, South Korea, ²Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Serositis is one of the classification criteria for systemic lupus erythematosus and a common type of extra renal flare. Comparison of associates of pleurisy…
Abstract Number: 810 • 2015 ACR/ARHP Annual Meeting
Human Parvovirus B19 Nonstructural Protein 1 (NS1) Helicase Breaks Tolerance to Self dsDNA: A Model for Viral Induction of Autoimmunity
Heidi Pirttinen¹, Kanoktip Puttaraksa¹, Robert J. Lagier², Stanley J. Naides³ and Leona Gilbert¹, ¹Department of Biological and Environmental Science, University of Jyväskylä, Jyväskylä, Finland, ²Research Support, Alameda, Quest Diagnostics Alameda, Alameda, CA, ³Immunology, Quest Diagnostics Nichols Institute, San Juan Capistrano, CA
Background/Purpose: B19 virus (B19V) is common, infects all ages, and is associated with various clinical syndromes including SLE-like autoimmunity. We previously demonstrated that B19 NS1,…
Abstract Number: 1760 • 2015 ACR/ARHP Annual Meeting
PD-1 Signaling Interferes with OX40 to Alter the Suppressive Function and Proliferation of CD4+ Regulatory T Cells in Lupus Mice
Maida Wong¹ and Bevra H. Hahn^2,3, ¹Division of Rheumatology, Department of Medicine, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, ²Medicine, UCLA David Geffen School of Medicine, Division of Rheumatology, Los Angeles, CA, ³Rheumatology, Professor Emeritus, Department of Medicine/Rheumatology, David Geffen School of Medicine UCLA, Los Angeles, CA
Background/Purpose: In systemic lupus erythematosus (SLE), the dysregulated production of autoantibodies is a consequence of disrupted T cell homeostasis. Programmed death-1 (PD1), a negative regulatory…
Abstract Number: 1859 • 2015 ACR/ARHP Annual Meeting
Anti-Interferon Autoantibodies in Systemic Lupus Erythematosus Are Biologically Active and Have Distinct Functions
Sarthak Gupta^1,2, Ioanna P. Tatouli³, Lindsey B. Rosen¹, Sarfaraz Hasni², Illias Alevizos⁴, Zerai G. Manna², Juan Rivera², Chao Jiang^2,5, Richard M. Siegel⁶, Steven M. Holland¹, Haralampos M. Moutsopoulos³ and Sarah K. Browne^1,7, ¹Laboratory of Clinical Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, ²National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ³Department of Pathophysiology, School of Medicine, National University of Athens, Athens, Greece, ⁴National Institute of Dental and Craniofacial Research, National Institutes of Health, Bethesda, MD, ⁵National Center for Complementary and Alternative Medicine, National Institutes of Health, Bethesda, MD, ⁶NIAMS, Immunoregulation Section, Autoimmunity Branch, Bethesda, MD, ⁷Office of Vaccines Research and Review, Center for Biologics Evaluation and Research, US Food and Drug Administration, Silver Spring, MD
Background/Purpose: Anticytokine autoantibodies are pathogenic in many hematologic, pulmonary and infectious diseases. However, a systematic investigation of their presence and significance in autoimmune diseases is…
Abstract Number: 2933 • 2015 ACR/ARHP Annual Meeting
Low Prevalence of PCP in Hospitalized Patients with SLE: Review of a Clinical Database Warehouse
Teja Kapoor¹, Jianhua Li², Sameer Malhotra³, Joan Bathon⁴ and Anca Askanase⁵, ¹Columbia University, New York, NY, ²Columbia University Medical Center, New York, NY, ³Weill Cornell Medical Center, New York, NY, ⁴Rheumatology, Columbia University Medical Center, NY, NY, ⁵Columbia University College of Physicians & Surgeons, New York, NY
Background/Purpose : The risk of Pneumocystis carinii pneumonia (PCP) in Systemic Lupus Erythematosus (SLE) is not well-established. Accordingly, this study aims to establish the prevalence…
Abstract Number: 733 • 2015 ACR/ARHP Annual Meeting
Late Onset Systemic Lupus Erythematosus: A Different Disease Subset?
Anne Riveros Frutos¹, Melania Martínez-Morillo¹, Irma Casas^2,3, Iñigo Rúa-Figueroa⁴, JM Pego-Reigosa⁵, M. Jesús García de Yebenes⁶, Alejandro Olivé¹, José Rosas⁷, Paloma Vela Casasempere⁸, Monica Ibanez Barcelo⁹, Vicente Torrente¹⁰, Ivan Castellvi¹¹, Javier Narváez¹², Mireia Moreno¹³, Ricardo Blanco¹⁴, Víctor Martínez Taboada¹⁵, Jaime Calvo¹⁶, Ángeles Aguirre Zamorano¹⁷, Mercedes Freire¹⁸, Enrique Raya¹⁹, Celia Erausquin²⁰, Esther Uriarte²¹, Elvira Diez Alvarez²², Tomás Vázquez Rodríguez²³, Antonio Fernandez-Nebro²⁴, Eva Tomero²⁵, Paloma García de la Peña²⁶, Ana Sánchez Atrio²⁷, Monica Fernandez Castro²⁸, Antonio Zea²⁹, Patricia Richi³⁰, Francisco Javier López Longo³¹, María Galindo³², Patricia E. Carreira³³, Gema Bonilla³⁴, Carlos Marras Fernandez-Cid³⁵, Maria Loreto Horcada³⁶, Carlos Alberto Montilla Morales³⁷, Blanca Hernández-Cruz³⁸, José Luis Marenco de la Fuente³⁹, Marian Gantes⁴⁰, Olaia Fernández Berrizbeitia⁴¹, Juan José Alegre⁴², Ángela Pecondón Español⁴³, Manuel Rodríguez-Gómez⁴⁴, Victor Quevedo⁴⁵, José Hernández Beiraín⁴⁶ and Lucía Silva Fernández⁴⁷, ¹Rheumatology, Hospital Universitari Germans Trias i Pujol, Barcelona, Spain, ²Preventive Medicine, Hospital Universitari Germans Trias i Pujol, Barcelona, Spain, ³preventive medicine, Hospital Universitari Germans Trias i Pujol, barcelona, Spain, ⁴Rheumatology, Hospital Universitario Dr. Negrin, Las Palmas de Gran Canarias, Spain, ⁵Rheumatology, Hospital Meixoeiro, Vigo, Spain, ⁶Research Unit of the SER, Madrid, Spain, ⁷Rheumatology, Hospital Marina Baixa, Villajoyosa, Spain, ⁸Rheumatology, Hospital General de Alicante, Alicante, Spain, ⁹H. Son Llatzer, Palma de Mallorca, Spain, ¹⁰Hospital Sant Joan de Déu, Esplugues de Llobregat, Spain, ¹¹Unitat de Reumatologia., Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, ¹²Rheumatology Department, Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Spain, ¹³Rheumatology, Hospital Parc Taulí, Sabadell, Spain, ¹⁴Reumatologia, Hospital Universitario Marques de Valdecilla, Santander, Spain, ¹⁵Rheumatology, Hospital Marqués de Valdecilla, Santander, Spain, ¹⁶Rheumatology, Hospital de Sierrallana, Torrelavega, Spain, ¹⁷Rheumatology, IMIBIC-Reina Sofia Hospital, Cordoba, Spain, ¹⁸Rheumatology, Hospital Universitario Juan Canalejo, La Coruña, Spain, ¹⁹Rheumatology, Hospital Clínico San Cecilio, Granada, Spain, ²⁰Rheumatology, Hospital de Gran Canaria Dr Negrin, Las Palmas GC, Spain, ²¹Reumatología, Hospital de Donosti, Donosti, Spain, ²²Rheumatology, Hospital de León, León, Spain, ²³Rheumatology, Hospital Lucus Augusti, Lugo, Spain, ²⁴Rheumatology, Hospital Universitario Carlos Haya, Malaga, Spain, ²⁵Hospital La Princesa. Madrid., Madrid, Spain, ²⁶Rheumatology, Hospital Universitario Madrid Norte Sanchinarro, Madrid, Spain, ²⁷Hospital Principe de Asturias. Madrid, Madrid, Spain, ²⁸Rheumatology, Hospital Puerta de Hierro, Madrid, Spain, ²⁹Hospital Ramón y Cajal, Madrid, Spain, ³⁰Hospital Infanta Sofía, Madrid, Spain, ³¹Hospital Gregorio Marañón, Madrid, Spain, ³²Rheumatology, Hospital 12 de octubre, Madrid, Spain, ³³Hospital 12 de Octubre, Madrid, Spain, ³⁴Rheumatology, Hospital La Paz, Madrid, Spain, ³⁵Hospital Virgen de la Arrixaca, Murcia, Spain, ³⁶Rheumatology, Complejo Hospitalario de Navarra, Pamplona, Spain, ³⁷Hospital Clínico Universitario de Salamanca, Salamanca, Spain, ³⁸Rheumatology, Hospital Universitario Virgen Macarena, Sevilla, Spain, ³⁹Rheumatology, Hospital de Valme, Seville, Spain, ⁴⁰Hospital Universitario de Canarias, Tenerife, Spain, ⁴¹Rheumatology, Basurto University Hospital, Bilbao, Spain, ⁴²Rheumatology Department, Hospital Universitario Doctor Peset, Valencia, Spain, ⁴³Rheumatology, Hospital Miguel Servet, Zaragoza, Spain, ⁴⁴Complejo Hospitalario Universitario de Ourense, Ourense, Spain, ⁴⁵Rheumatology, Hospital de Monforte, Lugo, Spain, ⁴⁶Rheumatology, Hospital Insular de Gran Canaria, Las palmas Gran Canarias, Spain, ⁴⁷Hospital Universitario de Guadalajara, Guadalajara, Spain
Background/Purpose: To describe the demographic, clinical and immunological manifestations in patients with late onset systemic lupus erythematosus (SLE) Methods: Patients diagnosed of SLE in the RELESSER data…
Abstract Number: 812 • 2015 ACR/ARHP Annual Meeting
SLAMF3 Mediated Co-Stimulation Promotes Activation of the IL-2/IL-2R/STAT5 Pathway and Regulatory T Cells Differentiation in Human Naïve CD4+ T Cells – Implications for SLE
Denis Comte^1,2, Maria P. Karampetsou¹, Katalin Kis-Toth¹, Nobuya Yoshida¹, Julie Solomon¹, Vasileios C. Kyttaris¹ and George C. Tsokos¹, ¹Division of Rheumatology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, ²Division of Immunology and Allergy, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
Background/Purpose: SLE is a multisystem autoimmune disease that displays quantitative and qualitative deficiencies of regulatory T cells (Treg), notably because of a compromised IL-2 production.…
Abstract Number: 1770 • 2015 ACR/ARHP Annual Meeting
A New Perspective in Extracorporeal Immunotherapy of Systemic Lupus Erythematosus: Dnase I-Based Blood Perfusion Experiment Using Rat Model
Ekaterina Simakova, Andrey Trofimenko, Ilya Gontar and Irina Zborovskaya, Research Institute of Clinical and Experimental Rheumatology, Volgograd, Russia
Background/Purpose: DNA, nucleosomes, and other deoxyribonucleoproteins (DNP) are currently believed to be the key autoantigens in SLE. However, these extracellular DNP itself appear to be…
Abstract Number: 1862 • 2015 ACR/ARHP Annual Meeting
Identification of Homogeneous Systemic Lupus Erythematosus (SLE) Patient Groups Using Clustered Autoantibody Reactivities
Petra Budde¹, Hans-Dieter Zucht¹, Daniel Chamrad¹, Anna Telaar¹, Johannes Schulte-Pelkum¹, Stefan Vordenbäumen², Peter Schulz-Knappe¹ and Matthias Schneider³, ¹Protagen AG, Dortmund, Germany, ²Department of Rheumatology, Univ. Duesseldorf, Düsseldorf, Germany, ³Rheumatology, Heinrich-Heine-University, Duesseldorf, Germany
Background/Purpose: In SLE, early diagnosis, differentiation to other autoimmune diseases and prognostic stratification are still great challenges. Hence, SLE represents an enormous challenge for the…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].